Innoviva (INVA) Work In Process (2012 - 2026)
Innoviva posted quarterly Work In Process of $17.3 million for Q1 2026, down 36.84% year-on-year from $27.4 million in Q1 2025, and down 3.07% on a QoQ basis from $17.9 million in Q4 2025.
Innoviva (INVA) has 8 years of Work In Process data on file, last reported at $17.3 million in Q1 2026.
- For the quarter ending Q1 2026, Work In Process fell 36.84% year-over-year to $17.3 million; the trailing twelve-month figure through Mar 2026 stood at $17.3 million (down 36.84% YoY), and the FY2025 full-year result was $17.9 million, down 12.95% from the prior year.
- Work In Process for Q1 2026 stood at $17.3 million, down from $17.9 million in the prior quarter.
- Across five years, Work In Process topped out at $54.1 million in Q3 2022 and bottomed at $13.2 million in Q3 2023.
- The 5-year median for Work In Process is $20.5 million (2024), against an average of $23.6 million.
- The widest annual swing landed in 2023, when Work In Process plunged 75.56%; it then jumped 54.18% in 2024.
- A 5-year view of Work In Process shows it stood at $25.1 million in 2022, then plunged by 37.45% to $15.7 million in 2023, then soared by 31.01% to $20.5 million in 2024, then retreated by 12.95% to $17.9 million in 2025, then retreated by 3.07% to $17.3 million in 2026.
- The last three Work In Process figures came in at $17.3 million (Q1 2026), $17.9 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.32 Mn |
| Dec 31, 2025 | 17.87 Mn |
| Sep 30, 2025 | 18.67 Mn |
| Jun 30, 2025 | 34.15 Mn |
| Mar 31, 2025 | 27.43 Mn |
| Dec 31, 2024 | 20.53 Mn |
| Sep 30, 2024 | 20.40 Mn |
| Jun 30, 2024 | 22.80 Mn |
| Mar 31, 2024 | 20.20 Mn |
| Dec 31, 2023 | 15.67 Mn |
| Sep 30, 2023 | 13.23 Mn |
| Jun 30, 2023 | 23.87 Mn |
| Mar 31, 2023 | 22.54 Mn |
| Dec 31, 2022 | 25.05 Mn |
| Sep 30, 2022 | 54.13 Mn |
| Mar 31, 2014 | 2.23 Mn |
| Dec 31, 2013 | 360,000.00 |
| Sep 30, 2013 | 3.61 Mn |
| Jun 30, 2013 | 4.71 Mn |
| Dec 31, 2012 | 1.85 Mn |